The Centers for Medicare & Medicaid Services (CMS) has launched a new, optional Substance Access Beneficiary Engagement Incentive (BEI) within select Innovation Center models, allowing participating providers to incorporate eligible hemp-derived products into patient care plans under clinician guidance. The initiative is now available to organizations in the ACO REACH Model and Enhancing Oncology Model, with expansion to the Long-term Enhanced ACO Design Model planned for 2027.
- Optional, model-specific tool: Participation is limited to select CMS Innovation Center models and is not system-wide
- Clinician-guided use: Eligible hemp-derived products may be included in care plans in accordance with model requirements and applicable laws
- No direct reimbursement: CMS will not cover or pay for these products under the BEI